Ίσως να είναι λίγο αργά, εγώ πάντως αυτό που καταλαβαίνω είναι ότι η χρήση βιοαπορροφήσιμων πολυμερών στα DES (Drug Eluting Stents = στεντ με απελευθέρωση φαρμάκου) σε αντιδιαστολή με τη μη χρήση τους ή με τα bare (metal) stents (γυμνά στεντ) έχει το πλεονέκτημα να μειώνει τις πιθανότητες επαναστένωσης, κάτι που αποτελεί σημαντικό πρόβλημα σε αντίστοιχες επεμβάσεις.

Το φαινόμενο catch-up είναι η αργή επαναφορά/επιστροφή του οργανισμού στην προηγούμενη κατάσταση (επαναγγείωση, επαναστένωση, κλπ) ανεξάρτητα από την παρουσία του στεντ ή ακόμα και η εμφάνιση κάποιου άλλου νοσήματος ή επιπλοκής λόγω της τοποθέτησης του στεντ.

Ρίξε μια ματιά:
Drug-eluting stents (DES) have markedly decreased in-stent restenosis (IRA) compared with bare metal stents (BMS) and balloon angioplasty. Late improvement in luminal diameter has been demonstrated with the use of BMS, but sirolimus-eluting stents have failed to show long-term inhibition of neointimal hyperplasia in a porcine model. The risk of late catch-up phenomenon (later progression of neointimal hyperplasia) remains.
http://www.summitmd.com/angioplasty/summitmd_eposter/eposter...



--------------------------------------------------
Note added at 4 hrs (2007-05-21 15:18:18 GMT)
--------------------------------------------------

Δες και εδώ:
Beneficial short-term results of any new therapy under evaluation do not always translate to lasting efficacy, and the issue of the “late catch-up” phenomenon is an important one given the recent unfavorable experience with vascular brachytherapy. Longer term results of trials have suggested that vascular brachytherapy delays rather than prevents restenosis. The 5-year follow-up data of the Scripps Coronary Radiation to Inhibit Proliferation Post-Stenting trial
showed the target lesion revascularization rate in the brachytherapy arm gradually increasing over the years (11.5% at 6 months, 15.4% at 3 years, and 23.1% at 5 years), despite the continuing significant difference compared with the control group. In addition, the 5-year results of the Gamma-1 study also showed that there was no onger any significant difference in the MACE or target
lesion revascularization rates between the irradiated and
control groups after 5 years.
In contrast to these late catch-up phenomena, our findings demonstrate sustained efficacy and safety up to 3 years after implantation of the polymer-based paclitaxel-eluting TAXUS stent. Annual follow-up through 5 years in all pivotal TAXUS trials will provide further valuable insights into the long-term benefit of this stent design.

http://www.sigmund-silber.com/publ/2005/05-Silber-AJC-TAXUS-...

--------------------------------------------------
Note added at 22 hrs (2007-05-22 09:49:23 GMT)
--------------------------------------------------

Έπειτα από τη συμβολή της Δανάης:

"Φαινόμενα επανεμφάνισης".